Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure Trial
Key result
Combined isosorbide dinitrate and hydralazine improves survival and outcomes in African-Americans with symptomatic heart failure and reduced ejection fraction.
Why the study?
Does the combination of isosorbide dinitrate and hydralazine improve outcomes in African-Americans with symptomatic heart failure and reduced ejection fraction?
Population
African-Americans with symptomatic heart failure and reduced ejection fraction
Comparison
Isosorbide dinitrate and hydralazine combination vs Placebo or other standard therapies
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports guideline-directed use in African-American HFrEF patients; confirms consistency of prior evidence via synthesis.
Structured PICO
Does the combination of isosorbide dinitrate and hydralazine improve outcomes in African-Americans with symptomatic heart failure and reduced ejection fraction?
P
Population
African-Americans with symptomatic heart failure and reduced ejection fraction
I
Intervention
Isosorbide dinitrate and hydralazine combination
C
Comparator
Placebo or other standard therapies (as discussed in historical trials like A-HeFT and V-HeFT)
O
Outcome
Mortality and morbidityhard clinical
This review reinforces the 2013 ACCF/AHA guideline recommendation for the use of combined isosorbide dinitrate and hydralazine to reduce mortality and morbidity in African-Americans with HFrEF.
Cite This Study
Ferdinand et al. (2014) conducted a review in Heart failure with reduced ejection fraction in African-Americans. Isosorbide dinitrate and hydralazine was evaluated. Combined isosorbide dinitrate and hydralazine improves survival and outcomes in African-Americans with symptomatic heart failure and reduced ejection fraction.